Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ivermectin.
- Who it may be relevant to
- Registry conditions: Survival of Flies Developing in Faecal Samples. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Impact of Oral Ivermectin (150 Micrograms/kg) on Musca Sorbens, the Putative Vector of Trachoma
Overview
Trachoma is caused by repeated Chlamydia trachomatis infection in the eye. Routes of infection include close person-to-person contact and contaminated clothing. In addition, the bazaar fly Musca sorbens has been implicated in transmission. These flies frequently visit the faces of children and have been found positive for C. trachomatis, which may be transferred from the body of the flies or their regurgitated or defecated material. This study aims to give recruited healthy volunteers a safe dose of oral ivermectin. Their faeces will be collected over subsequent days to determine whether ivermectin excreted from the body results in faecal concentrations that are high enough to prevent emergence of M. sorbens developing in faeces. It will also quantify ivermectin concentrations in tears secretions and faecal samples for up to 30 days post-treatment.
Interventions
- Drug Ivermectin
Oral dose of ivermectin (150 micrograms/kg)
Primary outcome measures
- Musca sorbens larvae surviving to adulthood [Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment]
Secondary outcome measures (4)
- Concentration of ivermectin in faeces [Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment]
- First oviposition event [Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment]
- Behvioural response [Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment]
- Adult fly survival [Time frame: Each time pointDays 1, 2, 3, 4, 5, 10 and 30 post treatment]
Eligibility criteria
Inclusion criteria
- Able and willing to give fully informed consent
- Able to understand and comply with the study procedures
- Able to produce a stool on most days
- Consider themselves to be in good general health
- Aged 18 to 65 years
Exclusion criteria
- Suspected or known to be sensitive or allergic to ivermectin
- Women who are pregnant, nursing or intending to become pregnant
- Aware of having any neurological disorders or recent history of seizures
- History of travel to a region endemic for Loa loa.
- Currently taking acenocoumarol, warfarin or levimasole
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
United Kingdom · 1 center
- London School of Hygiene & Tropical Medicine — London
Identifiers
NCT: NCT07657143 · 32885